| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD300LG; CLM9; TREM4; CMRF35-like molecule 9; CLM-9; CD300 antigen-like family member G; Triggering receptor expressed on myeloid cells 4; TREM-4; CD300g |
| Entrez GeneID | 146894 |
| WB Predicted band size | Calculated MW: 36 kDa; Observed MW: 36 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human CD300LG. AA range:41-90 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CD300LG抗体的参考文献示例(内容为模拟，仅供参考)：
---
1. **文献名称**：CD300LG as a Novel Immune Checkpoint Molecule in Tumor Microenvironment
**作者**：Smith A, et al.
**摘要**：本研究探讨CD300LG在肿瘤内皮细胞中的表达及其对T细胞功能的调控作用。通过开发特异性单克隆抗体，发现CD300LG的阻断可增强抗肿瘤免疫反应，提示其作为潜在免疫治疗靶点。
---
2. **文献名称**：Characterization of CD300LG Antibody for Vascular Endothelial Cell Analysis
**作者**：Zhang L, et al.
**摘要**：报道一种高亲和力抗CD300LG抗体的开发，验证其在流式细胞术和免疫荧光中的应用。研究发现CD300LG在炎症条件下表达上调，可能参与血管屏障功能的调节。
---
3. **文献名称**：CD300LG-Mediated Adhesion in Leukocyte Transmigration
**作者**：Tanaka K, et al.
**摘要**：通过功能实验和抗体阻断技术，证实CD300LG介导白细胞与内皮细胞的黏附过程，并揭示其与脂质配体相互作用的分子机制，为抗炎治疗提供新思路。
---
4. **文献名称**：CD300LG Expression Correlates with Prognosis in Colorectal Cancer
**作者**：Wang Y, et al.
**摘要**：利用CD300LG抗体对临床样本进行免疫组化分析，发现其低表达与结直肠癌患者预后不良相关，提示其可能作为生物标志物或治疗靶点。
---
**注**：以上内容为基于学术文献常见主题的模拟，实际文献需通过数据库(如PubMed、Web of Science)检索确认。如需具体文献，建议使用关键词“CD300LG antibody”或“CD300LG function”进一步查阅。
CD300LG, also known as CLM-9 or CMRF35A-like molecule, is a cell surface glycoprotein belonging to the CD300 family of immunoregulatory receptors. This family is characterized by immunoglobulin-like domains and plays roles in modulating immune responses, particularly in myeloid and endothelial cells. CD300LG is primarily expressed on vascular endothelial cells and certain immune cells, including dendritic cells and monocytes. It functions as a lipid-binding receptor, interacting with phospholipids such as phosphatidylserine (PS) and lysophosphatidylcholine (LPC), which are exposed on stressed or apoptotic cells. This interaction facilitates immune processes like phagocytosis, cell adhesion, and inflammation regulation.
CD300LG antibodies are tools used to study the protein's expression, localization, and function. They enable detection of CD300LG in experimental models, aiding research into vascular biology, immune tolerance, and inflammatory diseases. Recent studies suggest CD300LG may influence tumor angiogenesis and immune evasion, making it a potential therapeutic target. Antibodies targeting CD300LG are employed in techniques like flow cytometry, immunohistochemistry, and Western blotting. Their development also supports exploration of CD300LG's dual role as both a pro- and anti-inflammatory mediator, depending on cellular context and ligand engagement. Research continues to clarify its signaling pathways and clinical relevance in sepsis, cancer, and autoimmune disorders.
×
